2. Apoptosis Immunology/Inflammation PI3K/Akt/mTOR Epigenetics Stem Cell/Wnt Protein Tyrosine Kinase/RTK JAK/STAT Signaling Neuronal Signaling Membrane Transporter/Ion Channel NF-κB Metabolic Enzyme/Protease Vitamin D Related/Nuclear Receptor Cell Cycle/DNA Damage
  3. Apoptosis Pyroptosis AMPK Bcl-2 Family JAK STAT Calcium Channel Interleukin Related TNF Receptor SOD Reactive Oxygen Species (ROS) PPAR
  4. Calenduloside E

Calenduloside E is a pentacyclic triterpenoid saponin that can be extracted from the bark and roots of Aralia ovata, and has anti-inflammatory and anti-apoptotic activities. Calenduloside E alleviates atherosclerosis by regulating macrophage polarization, improves mitochondrial function by regulating the AMPK-SIRT3 pathway, and alleviates acute liver injury. In addition, Calenduloside E promotes the interaction between L-type calcium channels and Bcl-2 related apoptosis genes, inhibits calcium overload, and alleviates myocardial ischemia/reperfusion injury. Calenduloside E also improves non-alcoholic fatty liver disease by regulating heat shock-dependent pathways, and inhibits ROS mediated JAK1-STAT3 pathways to reduce cellular inflammatory responses.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

Calenduloside E

Calenduloside E 構造式

CAS 番号 : 26020-14-4

容量 価格（税別） 在庫状況 数量
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 487 在庫あり
Solution
10 mM * 1 mL in DMSO USD 487 在庫あり
Solid
5 mg $350 在庫あり
10 mg $500 在庫あり
25 mg $850 在庫あり
50 mg $1200 在庫あり
100 mg   お問い合わせ  
200 mg   お問い合わせ  

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 1 publication(s) in Google Scholar

Calenduloside E 関連抗体

Top Publications Citing Use of Products

AMPK アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示
NUAK1 NUAK2 AMPK AMPK α1β1γ1 AMPK α2β1γ1 AMPK α1β2γ1 AMPK α2β2γ1 BRSK1 BRSK2 HUNK AMPKα

Bcl-2 Family アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示
Bcl-2 Bcl-xL Bcl-W Mcl-1 Bfl-1 Bcl-B Bax Bak Bim BNIP3 Bad

JAK アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示
JAK1 JAK2 JAK3 Tyk2 JAK

STAT アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示
STAT3 STAT5 STAT6 STAT1

Calcium Channel アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示
N-type calcium channel L-type calcium channel P/Q-type calcium channel T-type calcium channel Calcium Channel

Interleukin Related アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22 IL-18

TNF Receptor アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示
TNFRSF1A/CD120a TNFRSF3/CD18 TNFRSF4 TNFRSF5/CD40 TNFRSF6/Fas/CD95 TNFRSF7/CD27 TNFRSF8/CD30 TNFRSF9/4-1BB/CD137 TNFRSF10B/DR5/CD262 TNFRSF12A/TWEAK TNFRSF16/NGF Receptor/CD271 TNFRSF18/GITR/CD357

PPAR アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示
PPARα PPARβ/δ PPARγ PPAR PPARδ

  • 生物活性

  • 純度とドキュメンテーション

  • 参考文献

  • カスタマーレビュー

製品説明

Calenduloside E is a pentacyclic triterpenoid saponin that can be extracted from the bark and roots of Aralia ovata, and has anti-inflammatory and anti-apoptotic activities. Calenduloside E alleviates atherosclerosis by regulating macrophage polarization, improves mitochondrial function by regulating the AMPK-SIRT3 pathway, and alleviates acute liver injury. In addition, Calenduloside E promotes the interaction between L-type calcium channels and Bcl-2 related apoptosis genes, inhibits calcium overload, and alleviates myocardial ischemia/reperfusion injury. Calenduloside E also improves non-alcoholic fatty liver disease by regulating heat shock-dependent pathways, and inhibits ROS mediated JAK1-STAT3 pathways to reduce cellular inflammatory responses[1][2][3][4][5][6].

Cellular Effect
Cell Line Type Value Description References
HCT-116 IC50
18 μM
Compound: OAG
Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay
10.1039/C5MD00502G
MCF7 IC50
11.33 μM
Compound: OAG
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
10.1039/C5MD00502G
MOLT-4 IC50
13.34 μM
Compound: OAG
Cytotoxicity against human MOLT4 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human MOLT4 cells assessed as reduction in cell viability after 72 hrs by MTT assay
10.1039/C5MD00502G
NCI-H460 IC50
6 μM
Compound: 18
Cytotoxicity against human NCI-H460 cells incubated for 72 hrs by cell-titer 96 aqueous non-radioactive cell proliferation assay
Cytotoxicity against human NCI-H460 cells incubated for 72 hrs by cell-titer 96 aqueous non-radioactive cell proliferation assay
[PMID: 26287548]
SK-BR-3 IC50
11.88 μM
Compound: OAG
Cytotoxicity against human SKBR3 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human SKBR3 cells assessed as reduction in cell viability after 72 hrs by MTT assay
10.1039/C5MD00502G
体外実験

Calenduloside E (1.25 μg/mL; 24 h) inhibits glycolysis-mediated M1 macrophage polarization[2].
Calenduloside E (1 μM; 2 h) alleviates LPS (HY-D1056)/D-galn-induced AML12 and LX2 cell damage and AMPK-SIRT3 signaling pathway protein expression[3].
Calenduloside E (0-16 μM; 24 h) inhibits inflammasome activation and pyroptosis in AML-12 cells stimulated by lipid mixture[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Calenduloside E 関連抗体

Western Blot Analysis[2]

Cell Line: ox-LDL-induced M1 macrophages
Concentration: 1.25 μg/mL
Incubation Time: 24 h
Result: Reduced the levels of IL-1 β, IL-6, PFKFB3, GLUT1 and LDHA.

Western Blot Analysis[3]

Cell Line: LPS/ d-galn-induced AML12 and LX2 cells
Concentration: 1 μM
Incubation Time: 2 h
Result: Reduced ROS and JC-1 levels, as well as cell apoptosis.

Immunofluorescence[5]

Cell Line: AML-12 cells stimulated with lipid mixture
Concentration: 2, 4, 8 and 16 μM
Incubation Time: 24 h
Result: Inhibited the increased expression of NLRP3, Caspase-1 p20, and IL-1β.
体内実験

Calenduloside E (11 mg/kg; i.g.; once daily for 16 weeks) reduces atherosclerotic plaque size, enhanced plaque stability, and reduced inflammatory responses in ApoE-/- mice[2].
Calenduloside E (15 and 30 mg/kg; i.g.; once daily for 7 days) inhibits hepatocyte apoptosis and reduced oxidative stress and immune inflammation in mice with acute liver injury induced by LPS (HY-D1056) and D-GalN[3].
Calenduloside E (7.5-30 mg/kg; i.g.; once daily for 3 days) restores sarcomere contraction and calcium transients in adult rat ventricular myocytes (ARVMs)[4].
Calenduloside E (5 and 10 mg/kg; i.g.; once daily for 4 weeks) improves liver injury, lipid accumulation, and profibrotic phenotypes in nonalcoholic fatty liver disease model mice and inhibits inflammasome activation and pyroptosis in the liver of mice[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: HFD-fed ApoE-/- mice[2]
Dosage: 11 mg/kg
Administration: i.g.；Once a day for 16 weeks
Result: Reduced the levels of IL-1β, IL-6, TNF-α, and monocyte chemoattractant protein-1 (MCP-1) in the serum of ApoE-/- mice.
Animal Model: LPS (HY-D1056)/dGalN-induced acute liver injury in mice[3]
Dosage: 15 and 30 mg/kg
Administration: i.g.; 1 time per day for 7 consecutive days
Result: Improved hepatocyte infiltration and reduced hepatocyte necrosis and shrinkage.
Reduced hepatocyte ROS levels and serum MDA levels, and increased GSH-Px and SOD levels.
Animal Model: Rat Model of MI/R Injury[4]
Dosage: 7.5, 15 and 30 mg/kg
Administration: i.g.; 1 time per day for 3 consecutive days
Result: Myocardial infarction area/risk area decreased to 53%, 38% and 43% respectively.
Restored the expression of calcium-regulating proteins, including calcium transporters (SERCA, a1C, RyR2, and NCX) to normal levels.
Animal Model: Establishment of NAFLD model in apoE-/- mice by western diet[5]
Dosage: 5 and 10 mg/kg
Administration: i.g.; 1 time per day for 4 weeks
Result: Reduced the expression of TNF-α, MCP-1, CCL2, Ly6c and cd68 in the liver.
Reversed the upregulation of lipogenic genes FASN, Srebpf, ACC and PPARγ and lipid uptake gene cd36.
Reduced the expression of NLRP3, pNLRC4, NLRC4, cleaved GSDMD, cleaved Caspase1 and IL-1β.
分子量

632.82

分子式

C36H56O9
CAS 番号
Appearance

Solid

Color

White to off-white

SMILES

C[C@]12[C@]3(C([C@@]4([H])[C@](C(O)=O)(CCC(C)(C)C4)CC3)=CC[C@]1([H])[C@@]5([C@@](C(C)([C@@H](O[C@]6([H])O[C@@H]([C@@H](O)[C@H](O)[C@H]6O)C(O)=O)CC5)C)([H])CC2)C)C
Structure Classification
Initial Source
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
溶剤 & 溶解度
体外: 

DMSO : 100 mg/mL (158.02 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.5802 mL 7.9011 mL 15.8023 mL
5 mM 0.3160 mL 1.5802 mL 3.1605 mL
10 mM 0.1580 mL 0.7901 mL 1.5802 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

一般には略語で表示されます：C1V1 = C2V2

濃度 （開始）

C1

×
体積 （開始）

V1

=
濃度 （終了）

C2

×
体積 （終了）

V2

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (3.95 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% Corn Oil

    Solubility: ≥ 2.5 mg/mL (3.95 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション

純度: 99.07%

COA (253 KB) HNMR (286 KB) LCMS (87 KB)

取扱説明書 (2659 KB)
参考文献

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 1.5802 mL 7.9011 mL 15.8023 mL 39.5057 mL
5 mM 0.3160 mL 1.5802 mL 3.1605 mL 7.9011 mL
10 mM 0.1580 mL 0.7901 mL 1.5802 mL 3.9506 mL
15 mM 0.1053 mL 0.5267 mL 1.0535 mL 2.6337 mL
20 mM 0.0790 mL 0.3951 mL 0.7901 mL 1.9753 mL
25 mM 0.0632 mL 0.3160 mL 0.6321 mL 1.5802 mL
30 mM 0.0527 mL 0.2634 mL 0.5267 mL 1.3169 mL
40 mM 0.0395 mL 0.1975 mL 0.3951 mL 0.9876 mL
50 mM 0.0316 mL 0.1580 mL 0.3160 mL 0.7901 mL
60 mM 0.0263 mL 0.1317 mL 0.2634 mL 0.6584 mL
80 mM 0.0198 mL 0.0988 mL 0.1975 mL 0.4938 mL
100 mM 0.0158 mL 0.0790 mL 0.1580 mL 0.3951 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Calenduloside E Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量   濃度   体積   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

一般には略語で表示されます：C1V1 = C2V2

濃度 （開始） × 体積 （開始） = 濃度 （終了） × 体積 （終了）
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Calenduloside E26020-14-4ApoptosisPyroptosisAMPKBcl-2 FamilyJAKSTATCalcium ChannelInterleukin RelatedTNF ReceptorSODReactive Oxygen Species (ROS)PPARAMP-activated protein kinaseJanus kinaseCa2+ channelsCa channelsILTumor Necrosis Factor ReceptorTNFRSuperoxide DismutasePeroxisome proliferator-activated receptorsInhibitorinhibitorinhibit

最近チェックした製品:

オンラインお問い合わせ

Your information is safe with us. * Required Fields.

製品名

  

カスタマ需要量 *

お名前 *

 

タイトル

メールアドレス *

 

電話番号 *

デパートメント

 

組纖名 *

市区町村

都道府県

国或いは地域 *

      

必ず会社名を記載ください。個人への返信は行いません。

備考

バルクお問い合わせ

Inquiry Information

製品名:
Calenduloside E
製品番号:
HY-N6850
数量:
MCE 日本正規代理店:

カスタマーレビュー

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

製品名

  

Lot #

お名前 *

 

メールアドレス *

電話番号 *

 

部門 *

組纖名 *

 

国或いは地域 *

備考

Request for HNMR Report

We have received your request and will respond to you as soon as possible.